analytical methods is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Biodistribution and mechanisms of action == Lithium compartmentalization was studied in 11 biosubstrates of rats when lithium ascorbate was taken at a dose of 1000 mg/kg. As part of a tubeless analysis of the dynamics of concentrations in whole blood, the following values of the pharmacokinetic parameters of lithium ascorbate were obtained: Cmax=50.59 µg/l, tmax=1.50 h, Clast=33.7 µg/l, AUCt=1750 µg/l*h, MRTt=22.9 h, Lz=0.005 1/h, T1/2=141 h, CL=0.029 l/h, Vd=5.9 l. Multichamber pharmacokinetic analysis showed that the stabilization of lithium levels in the blood is maintained by a special "depot" of lithium, apparently consisting of the aorta, femur and brain. Application of the method of functional linkage analysis suggested that the targeted accumulation of ascorbate anion in cells is due to the activity of vitamin C transport proteins SLC23A1, SLC23A2, SLC23A3. At the same time, lithium ions and ascorbate exhibit a synergistic effect. The main effects of lithium include the support of normal excitability central nervous system: by preventing excessive concentration of norepinephrine, regulation of sodium concentration in muscle cells (which is important for the tone of blood vessels), sensitivity of neurons to dopamine, which reduces the negative impact of stress.
Bacteria encode evolutionary predecessors of cGAS, called cGAS/DncV-like nucleotidyltransferases (CD-NTases), which detect bacteriophage infection and produce diverse nucleotide second messengers. The regulation of bacterial CD-NTase activation remains an open question. Recent research has shown that CD-NTase-associated protein 2 (Cap2) primes bacterial CD-NTases for activation through a ubiquitin transferase-like mechanism. A cryo-electron microscopy structure of the Cap2–CD-NTase complex reveals Cap2 as an all-in-one ubiquitin transferase-like protein, with distinct domains resembling eukaryotic E1 and E2 proteins. The structure captures a reactive-intermediate state with the CD-NTase C-terminus positioned in the Cap2 E1 active site and conjugated to AMP. Cap2 conjugates the CD-NTase C-terminus to a target molecule that primes the CD-NTase for increased cGAMP production. Additionally, a specific endopeptidase, Cap3, balances Cap2 activity by cleaving CD-NTase–target conjugates. This research demonstrates that bacteria control immune signaling using an ancient, minimized ubiquitin transferase-like system, providing insights into the evolution of E1 and E2 machinery across domains of life.
== Leadership == Phil Keiser became the second CEO of the franchise in June 2015 until his death in October 2016. Joe Koss followed him in January 2017 until retiring at the end of 2020. He was succeeded by Enrique "Rick" Silva in March 2021. Silva retired in April 2025 and was replaced with Julie Fussner, the first female CEO of the company. She was previously the chief marketing officer, and had been with the company since 2017.
The pepper plant is a perennial woody vine growing up to 4 m (13 ft) in height on supporting trees, poles, or trellises. It is a spreading vine, rooting readily where trailing stems touch the ground. The leaves are alternate, entire, 5 to 10 cm (2 to 4 in) long and 3 to 6 cm (1 to 2+1⁄2 in) across.
=== Concerns about the medical evidence === Much of the medical evidence presented at trial has been criticised by experts across several specialties, including neonatology, pathology, nursing, biochemistry and forensic toxicology. Points of scrutiny have included the prosecution's assertions that the infants were clinically stable before their collapses, that alternative explanations could be excluded, and that the alleged mechanisms of harm were medically plausible. Controversy has also arisen from the fact that the original post‑mortem reports for the infants—most of whom underwent autopsy—did not identify suspicious or unnatural causes of death. In February 2025, a panel organised and instructed by Letby's defence team that was led by neonatologist Shoo Lee released findings from their own review of the deaths and collapses (see: § Expert panel investigation). The panel claimed that all of the incidents could be explained by natural causes, substandard care, or a combination of both, and claimed no evidence of deliberate harm.
Sources: en.wikipedia.org
=== Clinical trials === PL9643, an ophthalmic solution, is being tested in phase 3 clinical trials to determine safety and efficacy in patients with dry eye. PL9643 activates MC1R, MC3R, MC4R and MC5R. Completed Phase 2 studies demonstrated positive results for the treatment of dry eye disease. Dersimelagon (MT-7117) is an orally administered MC1R agonist being tested in phase 3 clinical trials to evaluate safety and tolerability in patients with erythropoietic protoporphyria or X-linked protoporphyria. Resomelagon (AP1189) is an orally administered MC1R and MC3R agonist being tested in three phase 2 clinical trials to study safety and efficacy in patients with rheumatoid arthritis and idiopathic membranous nephropathy.
Blockage of voltage-dependent sodium channels (after activation of the channel, diclofenac inhibits its reactivation, also known as phase inhibition) Blockage of acid-sensing ion channels (ASICs) Positive allosteric modulation of KCNQ- and BK-potassium channels (diclofenac opens these channels, leading to hyperpolarization of the cell membrane) The duration of action (i.e., duration of pain relief) of a single dose is longer (6 to 8 h) than the drug's 1.2–2 h half-life. This may be partly due to its persistence for over 11 hours in synovial fluids.
== Causes == The cause of immunodeficiency varies depending on the nature of the disorder. The cause can be either genetic or acquired by malnutrition and poor sanitary conditions. Only for some genetic causes, the exact genes are known.
The European continental tradition (See: Realism) focused on humans within human-made environments, and included the so-called city symphony films such as Walter Ruttmann's Berlin: Symphony of a Metropolis (of which Grierson noted in an article that Berlin, represented what a documentary should not be); Alberto Cavalcanti's, Rien que les heures; and Dziga Vertov's Man with a Movie Camera. These films tend to feature people as products of their environment, and lean towards the avant-garde.
== Regulatory status == The regulatory status of theanine varies by country. It is sold as a dietary supplement across the United States and European Union. In Japan, L-theanine has been approved for use in all foods, with some restrictions in the case of infant foods. In the United States, the FDA considers it to be generally recognized as safe (GRAS) and allows its use as an ingredient in foods and beverages up to a maximum of 250 mg per serving. In 2003, the German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung, BfR), an agency of their Federal Ministry of Food and Agriculture, objected to the addition of isolated theanine to beverages. While it was estimated the quantity of green tea consumed by the average Japanese tea drinker per day contains about 20 mg of the substance, there were no studies measuring the amount of theanine being extracted by typical preparation methods, or the percentage lost by discarding the first infusion. Therefore, with the Japanese being exposed to possibly much less than 20 mg per day, it was the opinion of the BfR that pharmacological reactions to drinks typically containing 50 mg of theanine per 500 milliliters could not be excluded –reactions such as impairment of psychomotor skills and amplification of the sedating effects of alcohol and hypnotics.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.